Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD
Launched by PIERRE FABRE DERMO COSMETIQUE · Nov 28, 2022
Trial Information
Current as of January 14, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject aged between 18 to 50 years included
- • Subject suffering from Atopic Dermatitis according to the "U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis" (6)
- • Subject with mild to moderate Atopic Dermatitis with 20 \<= SCORAD \<= 40 at inclusion
- • Subject with flare frequency ≥ 4 on the target areas over the last year
- • Subject with a cutaneous target area, allowing the measurements, located on upper or lower limbs and defined as a usual AD flare area according to the subject
- * Subject with a target area with 22 \<= target SCORAD signs \<= 10 following:
- • Erythema ≥ 1
- • Dryness ≥ 1 1
- * Subject with a control area, allowing the measurements, located on upper or lower limbs and defined as :
- • A non- usual AD flare area according to the subject and the investigator
- • A sufficient distance from the cutaneous target area according to the investigator
- Exclusion Criteria:
- • Subject with a surinfected AD
- • Subject having any other dermatologic condition other than AD or characteristics (e.g: tatoo) on the target area liable to interfere with the study assessments
- • Subject with another dermatologic condition, acute or chronic or disease or history of disease considered by the investigator, liable to interfere with the study assessments, or hazardous for the subject or incompatible with the study according to the investigator
- • Any surgical intervention on upper or lower limbs during the previous weeks or months liable to interfere with the study data according to the investigator
- • Systemic immunosuppressive therapy (excepted systemic corticoids) within 3 months before the inclusion visit or ongoing at inclusion visit (except during flare period)
- • Systemic corticoids taken within 4 weeks before the inclusion visit or ongoing at inclusion visit (except during flare period)
- • Phototherapy performed within 4 weeks before the inclusion visit or ongoing at inclusion visit (except during flare period)
- • Systemic antibiotics taken within 7 days before the inclusion visit or ongoing at inclusion visit (except during flare period)
- • Moderate to high-potency topical corticosteroids applied within 7 days on upper or lower limbs before the inclusion visit or ongoing at inclusion visit (except during flare period)
- • Topical immunomodulators, applied within 7 days on upper or lower limbs before the inclusion visit or ongoing at inclusion visit (except during flare period)
- • Topical or oral treatment instaurated or modified before the inclusion visit or planned to be instaurated during the study or ongoing at inclusion visit, liable to interfere with the study, according to the investigator
About Pierre Fabre Dermo Cosmetique
Pierre Fabre Dermo-Cosmétique is a leading global player in the dermatology and dermo-cosmetics sectors, dedicated to developing innovative products that address a wide range of skin conditions and enhance skin health. Established as a subsidiary of Pierre Fabre Group, the company combines scientific expertise with a commitment to quality and efficacy, ensuring that its offerings are grounded in rigorous research and clinical validation. With a strong portfolio of brands, Pierre Fabre Dermo-Cosmétique focuses on patient-centric solutions, aiming to improve the quality of life for individuals with sensitive or compromised skin. The company's strategic approach to clinical trials underscores its dedication to advancing dermatological science and delivering reliable, safe products to healthcare professionals and consumers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials